Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health

Patrick A. Flume, Brian P. O'Sullivan, Karen A. Robinson, Christopher H. Goss, Peter J. Mogayzel, Donna Beth Willey-Courand, Janet Bujan, Jonathan Finder, Mary Lester, Lynne Quittell, Randall Rosenblatt, Robert L. Vender, Leslie Hazle, Kathy Sabadosa, Bruce Marshall

Research output: Contribution to journalArticle

467 Citations (Scopus)

Abstract

Rationale: Cystic fibrosis is a recessive genetic disease characterized by dehydration of the airway surface liquid and impaired mucociliary clearance. As a result, individuals with the disease have difficulty clearing pathogens from the lung and experience chronic pulmonary infections and inflammation. Death is usually a result of respiratory failure. Newly introduced therapies and aggressive management of the lung disease have resulted in great improvements in length and quality of life, with the result that the median expected survival age has reached 36 years. However, as the number of treatments expands, the medical regimen becomes increasingly burdensome in time, money, and health resources. Hence, it is important that treatments should be recommended on the basis of available evidence of efficacy and safety. Objectives: The Cystic Fibrosis Foundation therefore established a committee to examine the clinical evidence for each therapy and to provide guidance for the prescription of these therapies. Methods: The committee members developed and refined a series of questions related to drug therapies used in the maintenance of pulmonary function. We addressed the questions in one of three ways, based on available evidence: (1) commissioned systematic review, (2) modified systematic review, or (3) summary of existing Cochrane reviews. Conclusions: It is hoped that the guidelines provided in this article will facilitate the appropriate application of these treatments to improve and extend the lives of all individuals with cystic fibrosis.

Original languageEnglish (US)
Pages (from-to)957-969
Number of pages13
JournalAmerican journal of respiratory and critical care medicine
Volume176
Issue number10
DOIs
StatePublished - Nov 15 2007

Fingerprint

Cystic Fibrosis
Maintenance
Guidelines
Lung
Health
Therapeutics
Committee Membership
Mucociliary Clearance
Inborn Genetic Diseases
Health Resources
Dehydration
Respiratory Insufficiency
Lung Diseases
Prescriptions
Pneumonia
Quality of Life
Safety
Drug Therapy
Infection

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., ... Marshall, B. (2007). Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. American journal of respiratory and critical care medicine, 176(10), 957-969. https://doi.org/10.1164/rccm.200705-664OC
Flume, Patrick A. ; O'Sullivan, Brian P. ; Robinson, Karen A. ; Goss, Christopher H. ; Mogayzel, Peter J. ; Willey-Courand, Donna Beth ; Bujan, Janet ; Finder, Jonathan ; Lester, Mary ; Quittell, Lynne ; Rosenblatt, Randall ; Vender, Robert L. ; Hazle, Leslie ; Sabadosa, Kathy ; Marshall, Bruce. / Cystic fibrosis pulmonary guidelines : Chronic medications for maintenance of lung health. In: American journal of respiratory and critical care medicine. 2007 ; Vol. 176, No. 10. pp. 957-969.
@article{8a9a02989bd7483daaefac89f9e82653,
title = "Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health",
abstract = "Rationale: Cystic fibrosis is a recessive genetic disease characterized by dehydration of the airway surface liquid and impaired mucociliary clearance. As a result, individuals with the disease have difficulty clearing pathogens from the lung and experience chronic pulmonary infections and inflammation. Death is usually a result of respiratory failure. Newly introduced therapies and aggressive management of the lung disease have resulted in great improvements in length and quality of life, with the result that the median expected survival age has reached 36 years. However, as the number of treatments expands, the medical regimen becomes increasingly burdensome in time, money, and health resources. Hence, it is important that treatments should be recommended on the basis of available evidence of efficacy and safety. Objectives: The Cystic Fibrosis Foundation therefore established a committee to examine the clinical evidence for each therapy and to provide guidance for the prescription of these therapies. Methods: The committee members developed and refined a series of questions related to drug therapies used in the maintenance of pulmonary function. We addressed the questions in one of three ways, based on available evidence: (1) commissioned systematic review, (2) modified systematic review, or (3) summary of existing Cochrane reviews. Conclusions: It is hoped that the guidelines provided in this article will facilitate the appropriate application of these treatments to improve and extend the lives of all individuals with cystic fibrosis.",
author = "Flume, {Patrick A.} and O'Sullivan, {Brian P.} and Robinson, {Karen A.} and Goss, {Christopher H.} and Mogayzel, {Peter J.} and Willey-Courand, {Donna Beth} and Janet Bujan and Jonathan Finder and Mary Lester and Lynne Quittell and Randall Rosenblatt and Vender, {Robert L.} and Leslie Hazle and Kathy Sabadosa and Bruce Marshall",
year = "2007",
month = "11",
day = "15",
doi = "10.1164/rccm.200705-664OC",
language = "English (US)",
volume = "176",
pages = "957--969",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "10",

}

Flume, PA, O'Sullivan, BP, Robinson, KA, Goss, CH, Mogayzel, PJ, Willey-Courand, DB, Bujan, J, Finder, J, Lester, M, Quittell, L, Rosenblatt, R, Vender, RL, Hazle, L, Sabadosa, K & Marshall, B 2007, 'Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health', American journal of respiratory and critical care medicine, vol. 176, no. 10, pp. 957-969. https://doi.org/10.1164/rccm.200705-664OC

Cystic fibrosis pulmonary guidelines : Chronic medications for maintenance of lung health. / Flume, Patrick A.; O'Sullivan, Brian P.; Robinson, Karen A.; Goss, Christopher H.; Mogayzel, Peter J.; Willey-Courand, Donna Beth; Bujan, Janet; Finder, Jonathan; Lester, Mary; Quittell, Lynne; Rosenblatt, Randall; Vender, Robert L.; Hazle, Leslie; Sabadosa, Kathy; Marshall, Bruce.

In: American journal of respiratory and critical care medicine, Vol. 176, No. 10, 15.11.2007, p. 957-969.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cystic fibrosis pulmonary guidelines

T2 - Chronic medications for maintenance of lung health

AU - Flume, Patrick A.

AU - O'Sullivan, Brian P.

AU - Robinson, Karen A.

AU - Goss, Christopher H.

AU - Mogayzel, Peter J.

AU - Willey-Courand, Donna Beth

AU - Bujan, Janet

AU - Finder, Jonathan

AU - Lester, Mary

AU - Quittell, Lynne

AU - Rosenblatt, Randall

AU - Vender, Robert L.

AU - Hazle, Leslie

AU - Sabadosa, Kathy

AU - Marshall, Bruce

PY - 2007/11/15

Y1 - 2007/11/15

N2 - Rationale: Cystic fibrosis is a recessive genetic disease characterized by dehydration of the airway surface liquid and impaired mucociliary clearance. As a result, individuals with the disease have difficulty clearing pathogens from the lung and experience chronic pulmonary infections and inflammation. Death is usually a result of respiratory failure. Newly introduced therapies and aggressive management of the lung disease have resulted in great improvements in length and quality of life, with the result that the median expected survival age has reached 36 years. However, as the number of treatments expands, the medical regimen becomes increasingly burdensome in time, money, and health resources. Hence, it is important that treatments should be recommended on the basis of available evidence of efficacy and safety. Objectives: The Cystic Fibrosis Foundation therefore established a committee to examine the clinical evidence for each therapy and to provide guidance for the prescription of these therapies. Methods: The committee members developed and refined a series of questions related to drug therapies used in the maintenance of pulmonary function. We addressed the questions in one of three ways, based on available evidence: (1) commissioned systematic review, (2) modified systematic review, or (3) summary of existing Cochrane reviews. Conclusions: It is hoped that the guidelines provided in this article will facilitate the appropriate application of these treatments to improve and extend the lives of all individuals with cystic fibrosis.

AB - Rationale: Cystic fibrosis is a recessive genetic disease characterized by dehydration of the airway surface liquid and impaired mucociliary clearance. As a result, individuals with the disease have difficulty clearing pathogens from the lung and experience chronic pulmonary infections and inflammation. Death is usually a result of respiratory failure. Newly introduced therapies and aggressive management of the lung disease have resulted in great improvements in length and quality of life, with the result that the median expected survival age has reached 36 years. However, as the number of treatments expands, the medical regimen becomes increasingly burdensome in time, money, and health resources. Hence, it is important that treatments should be recommended on the basis of available evidence of efficacy and safety. Objectives: The Cystic Fibrosis Foundation therefore established a committee to examine the clinical evidence for each therapy and to provide guidance for the prescription of these therapies. Methods: The committee members developed and refined a series of questions related to drug therapies used in the maintenance of pulmonary function. We addressed the questions in one of three ways, based on available evidence: (1) commissioned systematic review, (2) modified systematic review, or (3) summary of existing Cochrane reviews. Conclusions: It is hoped that the guidelines provided in this article will facilitate the appropriate application of these treatments to improve and extend the lives of all individuals with cystic fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=36248953255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248953255&partnerID=8YFLogxK

U2 - 10.1164/rccm.200705-664OC

DO - 10.1164/rccm.200705-664OC

M3 - Article

C2 - 17761616

AN - SCOPUS:36248953255

VL - 176

SP - 957

EP - 969

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 10

ER -